Research map: Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments

Back to the article

Papers in this map

  1. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis · Steven R. Ytterberg · 2022 · 1819 citations · Cited by this paper
  2. INFLAMMATORY BOWEL DISEASES AND THE RISK OF CARDIOVASCULAR EVENTS — A LITERATURE REVIEW · Kacper Byczek · 2026 · Cites this paper
  3. Modified Crohn's Disease Exclusion Diet and exclusive enteral nutrition (EEN) resolve oral dysbiosis in pediatric Crohn's disease: a prospective cohort study · Gary P. Moran · 2026 · 1 citation · Related
  4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis · William J. Sandborn · 2017 · 1774 citations · Cited by this paper
  5. Interpreting oral dysbiosis during nutritional therapy in pediatric Crohn disease · Huan Xu · 2026 · Related
  6. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases · James D. Clark · 2014 · 607 citations · Cited by this paper
  7. Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study · 2026 · Related
  8. The Incidence of Deep Venous Thrombosis and Pulmonary Embolism among Patients with Inflammatory Bowel Disease: A Population-based Cohort Study · James Blanchard · 2001 · 579 citations · Cited by this paper
  9. Mast cell–derived IL-13 as a driver of Crohn disease–associated intestinal fibrosis · 2026 · Related
  10. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study · Michael D. Kappelman · 2011 · 305 citations · Cited by this paper
  11. Transmural healing is significantly associated with prevention of clinical relapse in Crohn’s disease · 2026 · Related
  12. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update · Lisa M DeTora · 2022 · 270 citations · Cited by this paper
  13. Colonoscopic and oral microbiota transplant therapy yield similar stool and neoterminal ileal engraftment profiles in a single-blind pilot randomized trial · 2026 · Related
  14. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study · Farzin Khosrow‐Khavar · 2022 · 170 citations · Cited by this paper
  15. Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD · 2026 · Related
  16. The convergence of racial and income disparities in health insurance coverage in the United States · De‐Chih Lee · 2021 · 132 citations · Cited by this paper
  17. Inflammatory bowel disease in the aging population · 2026 · Related
  18. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance · Lars Erik Kristensen · 2023 · 127 citations · Cited by this paper
  19. Inflammatory bowel disease and risk of perineal injury in primiparous vaginal births: a retrospective cohort study · 2026 · Related
  20. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience · Sailish Honap · 2020 · 125 citations · Cited by this paper
  21. Increased risk of respiratory syncytial virus infection in patients with active inflammatory bowel disease: a matched cohort study · 2026 · Related
  22. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis · Parakkal Deepak · 2020 · 109 citations · Cited by this paper
  23. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry · María Chaparro · 2020 · 105 citations · Cited by this paper
  24. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis · Loriane Lair-Mehiri · 2019 · 77 citations · Cited by this paper
  25. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty · Bharati D. Kochar · 2021 · 50 citations · Cited by this paper
  26. Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases · Bharati D. Kochar · 2022 · 45 citations · Cited by this paper
  27. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases · Siddharth Singh · 2021 · 42 citations · Cited by this paper
  28. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data · Jeffrey R. Curtis · 2020 · 35 citations · Cited by this paper
  29. Inpatient Versus Outpatient Acute Venous Thromboembolism Management: Trends and Postacute Healthcare Utilization From 2011 to 2018 · Pamela L. Lutsey · 2021 · 26 citations · Cited by this paper
  30. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study · Rishi J. Desai · 2017 · 18 citations · Cited by this paper
  31. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis · Amy Yu · 2023 · 17 citations · Cited by this paper
  32. The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study · Johanna Holmgren · 2022 · 10 citations · Cited by this paper
  33. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis · Michael V. Chiorean · 2022 · 8 citations · Cited by this paper
  34. Private health insurance in the United States and Sweden: A comparative review · Udit Dave · 2024 · 8 citations · Cited by this paper
  35. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance · Jie Zhang · 2020 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)